Counter-intuitive as it may be, investing in areas that pharma is abandoning could yield great returns for investors. Just look at anti-bacterials in the ’90s and 2000s, says VC Bruce Booth in a Forbes column. So where should investors be looking today? Neuroscience, heart failure and obesity.
The shortage of cancer drugs that’s plagued hospitals for almost two years now has eased, although not completely, according to cancer doctors.
A recent study by Johns Hopkins researchers brings a reality check to the potential (and the limits) of genome sequencing in predicting disease.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Johnson & Johnson and Bristol-Myers Squibb both reported good news on their cancer drugs over the weekend. JNJ’s Zytiga slowed prostate cancer growth in a study of patients who hadn’t undergone chemotherapy, which will help the pharma in seeking approval for expanded use of the drug. And BMY has promising data for an experimental immunotherapy drug that could fight three types of cancer.
This new app developed by researchers at the University of Missouri encourages people to stick out their tongues during photos. It uses the Chinese concept of zheng to determine illness by analyzing color and coatings on the tongue.
